Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Protara Therapeutics, Inc. Director's Dealing 2020

Jun 11, 2020

34057_dirs_2020-06-11_ba61438d-3e52-44fc-a01f-83f081861201.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2020-06-09

Reporting Person: Solomon Michael Edward (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-06-09 Stock Option (Right to Buy) $35.00 A 9000 Acquired 2030-06-08 Common Stock (9000) Direct

Footnotes

F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.